Who is a candidate for hormone therapy?
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Short answer
Most healthy women with bothersome hot flashes or night sweats who start hormone therapy under age 60, or within 10 years of their final period, are candidates. The Menopause Society states that benefits particularly outweigh risks in early menopause. Breast cancer, unexplained vaginal bleeding, a history of clots or stroke, and active liver disease are contraindications.
Hormone therapy is a candidate treatment for most healthy women with bothersome menopause symptoms who are under 60 or within 10 years of their final period. The Menopause Society puts it plainly: benefits particularly outweigh the risks when hormone therapy is used in early menopause. The decision turns on three things: what symptoms you have, how far you are from your final period, and what is in your personal and family history.
What hormone therapy is approved to treat
Estrogen products carry four approved indications on their FDA labels: moderate to severe hot flashes and night sweats, moderate to severe vaginal and vulvar atrophy, low estrogen from hypogonadism or removal of the ovaries, and prevention of postmenopausal osteoporosis. Hormone therapy is not approved to prevent heart disease, to prevent dementia, or to treat weight gain. Women with premature or early menopause are a distinct group, usually treated at least until the average age of natural menopause because of the bone and cardiovascular consequences of early estrogen loss.
Who should not take systemic estrogen
Systemic estrogen labels list clear contraindications: undiagnosed abnormal genital bleeding, current or previous breast cancer, estrogen dependent cancer, active or previous deep vein thrombosis or pulmonary embolism, active or previous arterial clotting events such as stroke or heart attack, liver impairment or disease, and known thrombophilic disorders such as protein C, protein S or antithrombin deficiency. Several of these are absolute. Others, such as a strong family history of breast cancer or migraine with aura, call for a route and dose discussion rather than an automatic no.
What changed on the label in 2025
On 10 November 2025 the FDA required removal of the boxed warning covering cardiovascular disease, breast cancer and probable dementia from hormone therapy products, retaining the endometrial cancer boxed warning on systemic estrogen alone products. The agency argued the warning was based on a trial whose average participant was 63 years old, more than a decade past the average age of menopause. The underlying risks did not change on that date. What changed is how they are presented.
| Situation | Usual approach |
|---|---|
| Age under 60, within 10 years of final period, bothersome hot flashes | Systemic hormone therapy is a reasonable first line option |
| Vaginal dryness or painful sex only | Low dose vaginal estrogen, without systemic therapy |
| Over 60 or more than 10 years past the final period | Individualised discussion, lower doses, transdermal route usually preferred |
| Breast cancer history or active clotting disease | Non-hormonal treatment |
Come to the conversation with your final period date, your symptom list ranked by what actually disrupts your life, your blood pressure, and your family history of breast cancer, clots and early heart disease. Ask which symptom the prescription is meant to fix and how you will both know within 12 weeks whether it worked.
The clinical detail
Any woman with an intact uterus taking systemic estrogen needs a progestogen for endometrial protection. Low dose vaginal estrogen for genitourinary symptoms delivers minimal systemic exposure and does not require a progestogen. Estrogen labels carry four indications: moderate to severe vasomotor symptoms, moderate to severe vulvar and vaginal atrophy, hypoestrogenism from hypogonadism or castration or primary ovarian failure, and prevention of postmenopausal osteoporosis. The FDA action of 10 November 2025 removed boxed warnings for cardiovascular disease, breast cancer and probable dementia while retaining the endometrial cancer boxed warning for systemic estrogen alone products.
Written and medically reviewed by Zahraa Sater, M.D., M.P.H.
Reviewed August 12, 2026 · Next review due August 12, 2028
Sources
- Hormone Therapy. The Menopause Society
- Position Statements, including the 2022 Hormone Therapy and 2023 Nonhormone Therapy statements. The Menopause Society. PMID 35797481
- Estradiol Transdermal System, full prescribing information. DailyMed, U.S. National Library of Medicine
- HHS Advances Women's Health, Removes Misleading FDA Warnings on Hormone Replacement Therapy. U.S. Food and Drug Administration
This library is educational and is not individual medical advice. Read our Editorial and Medical Review Policy.